How to add a peptide program to your clinic in 90 days.

Most clinics that fail at peptides don't fail because the science is wrong. They fail because nobody helped them build the operating program — protocols, supply, staff training, marketing, intake, follow-up. This guide walks the entire arc from kickoff to a program that runs itself, in the order a real clinic needs to do it.

Week 1 — Audit

Before any compound gets ordered, the clinic needs an honest map of where it stands. The audit covers four things: current patient base, existing services that peptides can attach to, compliance posture, and operational capacity.

Patient base matters because peptide demand is patient-segment-specific. A med spa serving aesthetics-driven clients in their 40s converts strongly on GLP-1 weight management and NAD+ longevity. A TRT clinic serving men 35–65 converts on growth-hormone-releasing peptides and BPC-157 for recovery. A functional medicine practice serving complex-case patients converts on individualized protocols across longevity, gut, sleep, and cognition. The same compound is sold differently to each segment — the audit identifies which 2–3 peptides should anchor the launch.

Compliance posture means an honest read on the clinic's regulatory standing — current pharmacy partners, state licensing, prescribing scope, marketing channels in use, and whether the clinic has had any payment-processor or platform issues (LegitScript, Meta restrictions, processor risk flags). This determines what marketing channels are realistic and which pharmacy partners are accessible.

Operational capacity is the unsexy variable that decides timeline. A clinic with one MD and a single front-desk admin launches differently than a clinic with a medical director, three providers, and a back-office team. The audit produces a realistic 30/60/90-day timeline based on actual staff bandwidth — not on what would be ideal.

Weeks 2–3 — Source

Sourcing is the step most clinics get wrong. The choice between a 503A patient-specific compounding pharmacy and a 503B FDA-registered outsourcing facility is not a preference — it's a workflow constraint.

503A pharmacies dispense against a valid prescription for a specific patient. The clinic submits the prescription, the pharmacy compounds it, and it ships to the patient or the clinic for that patient. This is the right path for individualized dosing, complex protocols, and any compound that needs patient-by-patient customization (most peptide protocols).

503B outsourcing facilities are FDA-registered to compound in larger batches and can ship office-use inventory to the clinic — vials sitting on the shelf that any qualifying patient can receive. This is the right path for high-volume single-protocol programs (GLP-1 weight management at scale, NAD+ IV inventory) where individualization is minimal and turnaround speed matters.

Most clinics need both — 503A for individualized work and 503B for the high-volume backbone. Revival RX Partners opens accounts with the right partners for the clinic's actual protocols, not a generic list.

Compound shortlist for a launch

• Semaglutide (GLP-1) — weight management, the gateway compound for most clinics
• Tirzepatide (GLP-1/GIP) — second-line weight management, premium positioning
• BPC-157 — injury recovery, gut healing, broad-appeal adjunct
• TB-500 — soft-tissue recovery, common with athletic patient bases
• NAD+ — cellular energy, paired with IV therapy or IM dosing
• Sermorelin / Ipamorelin — growth hormone secretagogues for TRT and longevity

A clinic does not need all six to launch. Two well-protocolled compounds with confident clinical talk tracks convert better than six the staff barely knows.

Weeks 4–6 — Launch

Launch is where most clinics underinvest. The first patient through the program teaches the clinic more than any planning meeting — but only if the workflow is built to capture it.

Staff training

Every patient-facing team member — front desk, MAs, NPs, MDs — needs the same talk track. What the peptide does. What it costs. What the first 30 days look like. What the consult covers. Without this, the team unintentionally talks patients out of programs they would have bought. Training is live, not a PDF. It runs in 60-minute sessions across the first three weeks, with the front desk getting the most reps because they handle the most conversion-critical touchpoints.

Intake and consent

The intake workflow needs medical history, current medications, contraindications, and informed consent for compounded medications. This is HIPAA territory — paper intake works at small scale but a digital intake (Jotform HIPAA, IntakeQ, or the EHR's native flow) scales better and prevents the back-and-forth that kills consult-to-patient conversion.

First-month patient experience

The first 30 days post-prescription is where the program is won or lost. Patients need: a clear dosing schedule, an answer-line for side effects, a 14-day check-in (text or call, no charge), and a 30-day follow-up consult. Clinics that build this cadence retain peptide patients into 6 and 12-month programs. Clinics that ship the script and disappear churn the patient inside 60 days.

Months 2–12 — Scale

By month two the program has 5–15 patients and the workflow is stable. Scaling means three parallel motions.

Patient acquisition

Marketing channels for peptide clinics are constrained. Meta Ads has aggressive restrictions on weight-loss claims and prescription medications — most peptide ads run into LegitScript or personal-attribute flags. Google Search is more reliable for medical-intent queries but requires LegitScript certification for branded-drug bidding. Email and SMS to the existing patient base is the highest-converting channel by far — most clinics underestimate how many existing patients would say yes if offered a peptide consult.

Protocol expansion

Once the launch compounds are running cleanly, the clinic earns the right to layer in adjacent protocols — moving from Semaglutide alone to Semaglutide plus B12 or B-complex; from BPC-157 alone to BPC-157 plus TB-500 stacks; from single-peptide growth-hormone protocols to seasonal cycling. Each addition is a new revenue line per patient.

Operations

By month six the program is generating enough monthly revenue to justify a part-time peptide-specific role — either a dedicated NP/PA running peptide consults or a patient-care coordinator managing the follow-up cadence. Until that role exists, the medical director's time is the bottleneck on growth.

What to expect in real numbers

Realistic results, not invented metrics: a clinic that launches with two compounds and follows the 90-day plan typically has 10–25 active peptide patients by end of month three, 30–60 by end of month six, and a mature program of 75+ active patients by end of year one. Revenue per patient varies widely by protocol — GLP-1 weight management programs average $300–$600 per month per patient depending on dose and compound; growth-hormone secretagogue protocols sit in the $400–$800 monthly range; recovery-stack programs (BPC + TB) are typically $250–$450 per month.

These are operational averages, not promises. A clinic with a strong existing patient base and a well-positioned brand scales faster. A clinic launching cold takes longer. Either way, the program is the highest-margin revenue line in the practice once it's running — which is why the operational discipline of the first 90 days matters.

The shortcut

Revival RX Partners is built around this arc. Clinics open a free wholesale account, Brad walks the clinic through the partner-pharmacy options on the intro call, and ordering starts within 5 business days. Strategy, protocol depth, and ongoing support come with the relationship — not behind a subscription wall.